文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

维持性血液透析患者的个体化低温透析液(MyTEMP):一项实用性集群随机试验

Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial.
PubMed 文献 · Lancet · 2022-11-04
一句话结论在安大略省84个透析中心中,中心范围实施个体化低温透析液未显著降低主要心血管事件风险(校正HR 1.00,96%CI 0.89-1.11;p=0.93)。

MyTEMP是一项在加拿大安大略省透析中心进行的实用性、两臂、平行组、基于登记、开放标签、集群随机、优效性试验。84个中心按1:1随机分配至个体化低温透析液组(护士将透析液温度设定为低于每位患者透析前实测体温0.5-0.9°C,最低推荐透析液温度为35.5°C)或标准温度透析液组(所有患者和治疗均为36.5°C)。2017年4月3日至2021年3月31日期间,共15 413例患者接受门诊维持性血液透析(约430万次血液透析治疗)。主要复合终点(心血管相关死亡或因心肌梗死、缺血性卒中或充血性心力衰竭住院)在低温透析液组8000例患者中发生1711例(21.4%),标准温度组7413例中发生1658例(22.4%)(校正风险比1.00,96%CI 0.89-1.11;p=0.93)。作者认为该研究对低温透析液日益流行的趋势提出了质疑,部分患者人群中低温透析液的风险与获益应在未来试验中明确。

要点

  • 主要复合终点:低温透析液组1711/8000例(21.4%)vs 标准温度组1658/7413例(22.4%),校正HR 1.00(96%CI 0.89-1.11;p=0.93)。
  • 透析中收缩压平均下降:低温透析液组26.6 mm Hg vs 标准温度组27.1 mm Hg,平均差-0.5 mm Hg(99%CI -1.4至0.4;p=0.14)。
  • 实际平均透析液温度:低温透析液组35.8°C,标准温度组36.4°C。
  • 作者认为,与标准温度透析液相比,中心范围实施个体化低温透析液未显著降低主要心血管事件风险。
  • 作者认为,该研究对低温透析液日益流行的趋势提出了质疑,部分患者人群中低温透析液的风险与获益应在未来试验中明确。

适用人群与场景

  • 纳入标准:安大略省提供维持性血液透析、每周至少15例患者的透析中心;每个中心的医疗主任须确认其中心将实施分配的干预。
  • 排除标准:每周不足15例患者的中心;一个主任要求其7个中心中的4个不参与。
  • 场景:门诊维持性血液透析中心,非急诊或ICU场景。

处置流程与药物剂量

  • 个体化低温透析液组:护士将透析液温度设定为低于每位患者透析前实测体温0.5-0.9°C,最低推荐透析液温度为35.5°C。
  • 标准温度透析液组:所有患者和所有治疗均使用36.5°C透析液温度。

研究设计与关键结果

  • 研究设计:实用性、两臂、平行组、基于登记、开放标签、集群随机、优效性试验;在加拿大安大略省透析中心进行;84个中心按1:1随机分配至个体化低温透析液组(42个中心)或标准温度透析液组(42个中心)。
  • 评估了安大略省全部97个中心;9个中心患者少于15例,一个主任要求其7个中心中的4个不参与;最终招募84个中心,于2017年2月1日随机分组。
  • 干预期:2017年4月3日至2021年3月31日;期间试验中心为15 413例患者提供门诊维持性血液透析(约430万次血液透析治疗)。
  • 平均透析液温度:低温透析液组35.8°C,标准温度组36.4°C。
  • 主要复合终点(心血管相关死亡或因心肌梗死、缺血性卒中或充血性心力衰竭住院):低温透析液组1711/8000例(21.4%)vs 标准温度组1658/7413例(22.4%);校正HR 1.00(96%CI 0.89-1.11;p=0.93)。
  • 透析中收缩压平均下降:低温透析液组26.6 mm Hg vs 标准温度组27.1 mm Hg;平均差-0.5 mm Hg(99%CI -1.4至0.4;p=0.14)。
  • 主要终点由不知晓试验或中心分组情况的医疗编码员记录于省级数据库;分析按意向性治疗进行。

证据类型、等级与局限

  • 证据类型:实用性、集群随机、优效性试验;开放标签(患者和医疗提供者未设盲),但主要终点由不知晓分组的人员从省级数据库记录。
  • 样本量:84个中心,15 413例患者,约430万次血液透析治疗。
  • 局限:患者和医疗提供者未对分组设盲;作者认为部分患者人群中低温透析液的风险与获益应在未来试验中明确。

对床旁实践的改变

  • 作者认为,与标准温度透析液相比,中心范围实施个体化低温透析液未显著降低主要心血管事件风险。
  • 作者认为,该研究对低温透析液日益流行的趋势提出了质疑,部分患者人群中低温透析液的风险与获益应在未来试验中明确。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Haemodialysis centres have conventionally provided maintenance haemodialysis using a standard dialysate temperature (eg, 36·5°C) for all patients. Many centres now use cooler dialysate (eg, 36·0°C or lower) for potential cardiovascular benefits. We aimed to assess whether personalised cooler dialysate, implemented as centre-wide policy, reduced the risk of cardiovascular-related death or hospital admission compared with standard temperature dialysate.

METHODS: MyTEMP was a pragmatic, two-arm, parallel-group, registry-based, open-label, cluster-randomised, superiority trial done at haemodialysis centres in Ontario, Canada. Eligible centres provided maintenance haemodialysis to at least 15 patients a week, and the medical director of each centre had to confirm that their centre would deliver the assigned intervention. Using covariate-constrained randomisation, we allocated 84 centres (1:1) to use either personalised cooler dialysate (nurses set the dialysate temperature 0·5-0·9°C below each patient's measured pre-dialysis body temperature, with a lowest recommended dialysate temperature of 35·5°C), or standard temperature dialysate (36·5°C for all patients and treatments). Patients and health-care providers were not masked to the group assignment; however, the primary outcome was recorded in provincial databases by medical coders who were unaware of the trial or the centres' group assignment. The primary composite outcome was cardiovascular-related death or hospital admission with myocardial infarction, ischaemic stroke, or congestive heart failure during the 4-year trial period. Analysis was by intention to treat. The study is registered at ClinicalTrials.gov, NCT02628366.

FINDINGS: We assessed all of Ontario's 97 centres for inclusion into the study. Nine centres had less than 15 patients and one director requested that four of their seven centres not participate. 84 centres were recruited and on Feb 1, 2017, these centres were randomly assigned to administer personalised cooler dialysate (42 centres) or standard temperature dialysate (42 centres). The intervention period was from April 3, 2017, to March 31, 2021, and during this time the trial centres provided outpatient maintenance haemodialysis to 15 413 patients (about 4·3 million haemodialysis treatments). The mean dialysate temperature was 35·8°C in the cooler dialysate group and 36·4°C in the standard temperature group. The primary outcome occurred in 1711 (21·4%) of 8000 patients in the cooler dialysate group versus 1658 (22·4%) of 7413 patients in the standard temperature group (adjusted hazard ratio 1·00, 96% CI 0·89 to 1·11; p=0·93). The mean drop in intradialytic systolic blood pressure was 26·6 mm Hg in the cooler dialysate group and 27·1 mm Hg in the standard temperature group (mean difference -0·5 mm Hg, 99% CI -1·4 to 0·4; p=0·14).

INTERPRETATION: Centre-wide delivery of personalised cooler dialysate did not significantly reduce the risk of major cardiovascular events compared with standard temperature dialysate. The rising popularity of cooler dialysate is called into question by this study, and the risks and benefits of cooler dialysate in some patient populations should be clarified in future trials.

FUNDING: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Renal Network, Ontario Strategy for Patient-Oriented Research Support Unit, Dialysis Clinic, Inc., ICES (formerly known as the Institute for Clinical Evaluative Sciences), Lawson Health Research Institute, and Western University.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial. Lancet. 2022. PMID: 36343653. doi:10.1016/S0140-6736(22)01805-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。